NCT03125525 is a clinical trial of Cefaly device in Migraine, sponsored by Corfu Headache Clinic.

Who is sponsoring NCT03125525?

NCT03125525 is sponsored by Corfu Headache Clinic.

What drugs are being tested in NCT03125525?

Interventions in NCT03125525: Cefaly device.

Is NCT03125525 still recruiting?

NCT03125525 is currently completed. Last updated 24 April 2017.

Last reviewed 2017-04-24 · How we verify

NCT03125525

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Experience With Transcutaneous Supraorbital Nerve Stimulation in Refractory Migraine

Completed Last updated 24 April 2017

What this trial tests

trial testing Cefaly device in Migraine in 37 participants. Completed in 30 June 2016.

Timeline

1 January 2016

Primary endpoint
30 June 2016

30 June 2016

Quick facts

Lead sponsor	Corfu Headache Clinic
Status	Completed
Study type	OBSERVATIONAL
Enrollment	37
Start date	1 January 2016
Primary completion	30 June 2016
Estimated completion	30 June 2016

Drugs / interventions tested

Cefaly device

Conditions studied

Migraine — all drugs for Migraine →

Sponsor

Corfu Headache Clinic

Who can join

Eligibility, any sex, with Migraine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Migraine is included in the top-ten disabling diseases and conditions among the Western populations. Non-invasive neurostimulation (t-SMS), including the Cefaly® device, for the treatment of various types of pain is a relatively new field of interest. The aim of the present study was to explore the clinical experience with Cefaly® in a cohort of migraine patients previously refractory or non-tolerant to topiramate prophylaxis. Patients were followed prospectively after having been diagnosed with episodic or chronic migraine with a previous failure to topiramate treatment and having consented to receive preventive treatment with Cefaly® according to their treating physician's suggestion. A 1-month period of baseline observation was followed by a 3-month period of active treatment with transcutaneous supraorbital nerve stimulation (t-SNS) with Cefaly® as the only preventive treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study.
Vikelis M, Dermitzakis EV, Spingos KC, Vasiliadis GG, et al · · 2017 · cited 25× · PMID 28521762 · DOI 10.1186/s12883-017-0869-3
Neuromodulation Strategies to Reduce Inflammation and Improve Lung Complications in COVID-19 Patients.
Czura CJ, Bikson M, Charvet L, Chen JDZ, et al · · 2022 · cited 13× · PMID 35911909 · DOI 10.3389/fneur.2022.897124

Verify or expand the search:

Other recruiting trials for Migraine

Currently open trials in the same condition.

NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting

Other Corfu Headache Clinic trials

Trials by the same sponsor.

NCT04463875 — Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis · completed
NCT03606356 — Sustained onabotulinumtoxinA Therapeutic Benefits in Patients With Chronic Migraine · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03125525 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Corfu Headache Clinic
Last refreshed: 24 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03125525.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing